The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study

BACKGROUND: Patients treated with anti-epidermal growth factor receptor (anti-EGFR) will ultimately develop acquired resistance promoted by clonal selection, mainly the emergence of mutations in the MAPK pathway (mostly RAS mutations). Baseline assessment of RAS mutations in the blood of patients co...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Hsiang-Lin, Lin, Chun-Chi, Sung, Yung-Chung, Chen, Shang-Hung, Chen, Li-Tzong, Jiang, Jeng-Kai, Wang, Jaw-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491612/
https://www.ncbi.nlm.nih.gov/pubmed/37488448
http://dx.doi.org/10.1038/s41416-023-02366-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491612/
https://www.ncbi.nlm.nih.gov/pubmed/37488448
http://dx.doi.org/10.1038/s41416-023-02366-z

Ejemplares similares